Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Reported by Yahoo Finance · Published 8 Aug 2026, 12:36 AM MYT (1 hr ago)

Summary

Source & full coverage: this summary is aggregated from Yahoo Finance, the original publisher. Read the complete report for full context, data and quotes.

Read the original report at Yahoo Finance →

Most Recent

SpaceX’s stock is having one of its best days ever — with the first lockup expiration now behind it 1 hr ago BitMEX sale collapsed as buyers balked at founder ownership and shrinking business 1 hr ago Stocks Rise After Cooler-Than-Expected July Jobs Data 1 hr ago The $1 Million 401(k) Strategy That Doubles Your Annual Payout Before Age 59.5 1 hr ago Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling. 1 hr ago Stock Market Rally Powers Ahead; SpaceX, Palantir, Sandisk Are Key Earnings Movers: Weekly Review 1 hr ago

EconPulse

Markets. Economy. Malaysia & The World.

Independent economic news aggregation for Malaysia, Asia and global markets, updated throughout the day.

Company

About Us Editorial Standards & Corrections Privacy Policy

Work With Us

Submit a Press Release Partnerships & Advertising Contact Us RSS Feed

Contact

editor@econpulse.my

Editorial & newsroom enquiries answered within 1–2 business days.

Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.

Summary

More in Markets

SpaceX’s stock is having one of its best days ever — with the first lockup expiration now behind it

Stocks Rise After Cooler-Than-Expected July Jobs Data

The $1 Million 401(k) Strategy That Doubles Your Annual Payout Before Age 59.5

Stock Market Rally Powers Ahead; SpaceX, Palantir, Sandisk Are Key Earnings Movers: Weekly Review

Amazon's $220 billion AI bet hits a snag: Trainium 2 chips are only 20 months old and already being replaced

Miinor change in truck job numbers, bigger shift in warehouses